Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European...
Cancer
MSD Wins NMPA Approval for Keytruda-Lenvima Combo in Hepatocellular Carcinoma
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...
Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline
Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460),...
Abbisko Therapeutics Launches Clinical Study of FGFR4 Inhibitor in Advanced Hepatocellular Carcinoma
Shanghai-based Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced the dosing of the first patient in...
BioNTech in Deal to Acquire CureVac for $1.25B to Boost Cancer mRNA Therapies
Germany-based BioNTech SE (NASDAQ: BNTX) announced plans to acquire all outstanding shares of fellow German...
Bayzed Health Launches HK IPO to Expand Cancer Care Services
China-based Bayzed Health Group Inc. (HKG: 2609), a private healthcare provider specializing in oncology, has...
TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share
China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281...
Escugen Partners with SovranBio to Accelerate Development of Antibody-Drug Conjugates
Shanghai Escugen, a China-based clinical-stage company specializing in innovative antibody-drug conjugate (ADC) development, announced a...
China’s Sichuan Kelun-Biotech Wins BTD for Sac-TMT in Non-Squamous NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that its core product Jiatailai (sacituzumab...
Philochem Grants RayzeBio Global Rights to OncoACP3 for Prostate Cancer
Switzerland-based Philochem AG, a wholly-owned subsidiary of the Philogen Group (BIT: PHIL), announced a licensing...
Henlius Biotech Starts Global Phase II Trial for PD-L1 ADC HLX43
China’s Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a global,...
CSPC Pharma’s SYS6040 ADC Gains FDA Clinical Trial Approval
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...
Sino Biopharmaceutical’s TQB2868 Approved for Phase III Trial in Metastatic Pancreatic Cancer
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...
Sihuan Pharma’s Xuanyuening Granted New Indication Review in China
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
Novartis’ PSMAddition Trial Yields Positive Results for Pluvicto in mHSPC
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced the interim results from its Phase III PSMAddition...
Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs
China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced a strategic partnership with US-headquartered Medicovestor, Inc. to...
NeoCura Bio-Medical Gains NMPA Approval for mRNA Cancer Vaccine Trial
China-based NeoCura Bio-Medical Technology Co., Ltd. announced that it has received approval from the National...
Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Genrix Bio Partners with Cullinan Therapeutics for GR1803 License
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...
Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication
China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...